

# Correction for “Effectiveness of Subcutaneously Administered Leuprolide Acetate to Achieve Low Nadir Testosterone in Prostate Cancer Patients”

*Rev Urol.* 2018;20(2):63-68 doi: 10.3909/riu0798

[*Rev Urol.* 2019;21(2/3):144]

© 2019 MedReviews®, LLC

**D**ue to a typesetting error, there was an incorrect value listed in the y-axis, column 7, of Figure 3 on page 67 of Pieczonka CM et al. Effectiveness of subcutaneously administered leuprolide acetate to achieve low nadir testosterone in prostate cancer patients. *Rev Urol.* 2018;20(2):63-68. The corrected figure appears below and a corrected

PDF of the article may be found online at <http://medreviews.com/journal/reviews-in-urology/vol/20/no/2/effectiveness-subcutaneously-administered-leuprolide-acetate-achieve-low-nadir-testosterone-in-prostate-cancer-patients>.

We regret the inconvenience this error may have caused.




Figure 3. Proportion of patients by nadir testosterone level achieved over study duration (n = 437).